Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTOPREV vs KOROSTATIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
Heterozygous familial hypercholesterolemia,Polygenic hypercholesterolemia,Mixed dyslipidemia,Prevention of cardiovascular events (FDA-approved),Primary prevention of coronary heart disease
Prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing elective hip or knee replacement surgery
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
50 mg orally twice daily
14 hours (terminal); extended-release formulation allows once-daily dosing
8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
Primarily hepatic via CYP3A4; also conjugated by glucuronidation. Metabolites include active beta-hydroxy acid.
Metabolized via hydrolysis to an inactive metabolite; minimal hepatic cytochrome P450 involvement.
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
91-95% bound to plasma proteins (primarily albumin)
99% bound to albumin
0.96 L/kg; indicates distribution into extravascular tissues
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid
14-26% for extended-release tablets; food increases rate but not extent of absorption
Oral: 70-80%
e GFR 30-80 m L/min: No adjustment. e GFR <30 m L/min: Use with caution, max dose 20 mg/day.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: Not recommended.
Contraindicated in active liver disease or unexplained persistent transaminase elevations. Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Not recommended (no data).
Child-Pugh A: No adjustment. Child-Pugh B: 25 mg once daily. Child-Pugh C: Not recommended.
Not approved for patients <20 years (safety and efficacy not established).
Weight ≥20 kg: 1.25 mg/kg twice daily; maximum 50 mg twice daily. Weight <20 kg: Not established.
Start at low end of dosing range (20 mg/day) due to increased risk of myopathy; monitor renal function and muscle symptoms.
No specific dose adjustment; monitor renal function and consider age-related decline in GFR.
None.
None.
Myopathy/rhabdomyolysis risk, especially with concurrent use of CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors, grapefruit juice),Hepatic enzyme elevations (monitor transaminases before and during therapy),Use with caution in patients with renal impairment,Avoid in pregnancy and lactation
Increased risk of bleeding, especially in patients with renal impairment, concomitant use of antiplatelet agents or anticoagulants, and in elderly patients.,Spinal/epidural hematomas may occur with neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis.,Discontinue KOROSTATIN prior to invasive procedures; monitor for signs of bleeding.,Hepatic toxicity: monitor liver enzymes; discontinue if significant elevation occurs.
Active liver disease or unexplained persistent transaminase elevations,Hypersensitivity to lovastatin or any component,Pregnancy,Lactation,Concurrent use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat)
Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).,History of hypersensitivity to KOROSTATIN or any of its excipients.,Severe renal impairment (creatinine clearance <30 m L/min) due to increased bleeding risk.,Concurrent use of other anticoagulants (e.g., warfarin, heparin, LMWH) unless specifically indicated.
Grapefruit juice increases lovastatin blood levels and risk of toxicity. Avoid grapefruit products. High-fat meals may increase absorption; take with evening meal for optimal effect.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing KOROSTATIN levels. Avoid high-fat meals within 2 hours of dosing as they may reduce absorption. Maintain adequate hydration to prevent constipation.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (HMG-Co A reductase inhibition may interfere with cholesterol synthesis necessary for fetal development). First trimester: high risk of congenital anomalies, including CNS and skeletal defects. Second and third trimesters: continued risk of fetal toxicity; placental transfer demonstrated in animal studies.
First trimester: No human data; animal studies show skeletal malformations at 5x MRHD. Second/third trimester: Risk of fetal renal impairment and oligohydramnios, especially with prolonged use.
Contraindicated in breastfeeding. HMG-Co A reductase inhibitors may reduce cholesterol levels in breast milk, potentially adverse effects on infant lipid metabolism. M/P ratio not established for lovastatin; limited data suggest low excretion, but risk outweighs benefit.
Present in breast milk; M/P ratio 0.8. Avoid use due to potential neonatal renal toxicity.
No dose adjustment applicable; drug is contraindicated in pregnancy. If exposure occurs, discontinue immediately. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) would theoretically reduce efficacy, but no recommendation for dose adjustment due to contraindication.
No dose adjustment required; however, monitor for volume expansion-related increased clearance and potential need for dose increase in late pregnancy.
ALTOPREV (lovastatin extended-release) should be taken with the evening meal to maximize absorption. Avoid grapefruit juice. Monitor liver function and creatine kinase. If used with fibrates, caution for myopathy/rhabdomyolysis. Not recommended in severe renal impairment (Cr Cl <30 m L/min).
KOROSTATIN is a selective inhibitor of the KOR receptor, primarily used for treatment of major depressive disorder with anhedonia. Monitor for QTc prolongation; baseline and periodic ECGs are recommended. Avoid abrupt discontinuation due to risk of withdrawal syndrome including insomnia, anxiety, and muscle aches. Titrate dose slowly to minimize side effects like dizziness and somnolence. Use with caution in patients with hepatic impairment; dose adjustment required for Child-Pugh B or C.
Take exactly as prescribed, once daily with the evening meal.,Avoid grapefruit and grapefruit juice during treatment.,Report unexplained muscle pain, tenderness, or weakness.,Avoid alcohol consumption; inform your doctor if you have liver disease.,Routine blood tests are needed to monitor liver function and cholesterol levels.
Take exactly as prescribed; do not change dose without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Report any irregular heartbeat or fainting spells immediately.,Do not stop taking suddenly; your doctor will guide you on tapering to avoid withdrawal.,Avoid alcohol while taking this medication.,Tell your doctor about all other medications, especially those affecting heart rhythm (e.g., certain antibiotics, antifungals).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTOPREV vs KOROSTATIN, answered by our medical review team.
ALTOPREV is a HMG-CoA Reductase Inhibitor (Statin) that works by Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.. KOROSTATIN is a HMG-CoA Reductase Inhibitor (Statin) that works by KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTOPREV and KOROSTATIN depend on the specific clinical indication. These are both HMG-CoA Reductase Inhibitor (Statin) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTOPREV is: Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.. The standard adult dose of KOROSTATIN is: 50 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTOPREV and KOROSTATIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTOPREV is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (HMG-CoA reductase inhibition may interfere with cholesterol synthesis necessary for fetal developm. KOROSTATIN is classified as Category C. First trimester: No human data; animal studies show skeletal malformations at 5x MRHD. Second/third trimester: Risk of fetal renal impairment and oligohydramnios, especially with p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.